About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT05964946

Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

This was a non-interventional, retrospective, cross-sectional, descriptive study, conducted on the National Health Data System (Système National des Données de Santé, SNDS). The study did not modify ...

Lead sponsor: Novartis Pharmaceuticals•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Received at least one reimbursement of Ilaris® from 08 April 2018 to 07 April 2020.
•Benefited from at least one of the following healthcare consumptions during 3 years prior to index date:
•o At least one hospitalization with a main diagnosis or a related diagnosis in a Medical Unit Summary or a significant associated diagnosis in a Standardized Discharge Summary corresponding to the International Classification of Diseases, 10th Revision (ICD-10) code:
•* M10.0 "Idiopathic gout"
•* M10.1 "Saturnine gout"
•* M10.2 "Medicated gout"
•* M10.3 "Gout due to impaired renal function"
•* M10.4 "Other secondary gout"
•* M10.9 "Gout, unspecified"
•And/or an active long-term disease (Affection Longue Durée, ALD) with an ICD-10 code: "M10 Gout"
•And/or at least one dispensation of colchicine and urate-lowering therapy (allopurinol and/or febuxostat and/or benzbromarone and/or probenecid) at any time.

Exclusion Criteria

•None

Related studies

RECRUITINGPhase 2

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

NCT07453004 · Acute Gouty Arthritis

RECRUITINGPhase 2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746 · Gout, Gouty Arthritis, and more

COMPLETEDPhase 1

A Bioequivalence Study of Two Different Dosage Form of Genakumab

NCT06451848 · Gouty Arthritis (GA)

The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.

NCT05332795 · Gouty Arthritis

Treatment of Topical Ketorolac Gel in Acute Gouty Flare

NCT06273813 · Acute Gouty Arthritis, Acute Pain, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 28, 2023Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment15

Start dateJun 2020

Last updatedJul 28, 2023

Condition

Gouty Arthritis

Locations shown

Novartis

Paris

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 28, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions